These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 29214290)

  • 21. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
    Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
    J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
    Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
    JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
    Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J
    Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
    Beaver JA; Hazarika M; Mulkey F; Mushti S; Chen H; He K; Sridhara R; Goldberg KB; Chuk MK; Chi DC; Chang J; Barone A; Balasubramaniam S; Blumenthal GM; Keegan P; Pazdur R; Theoret MR
    Lancet Oncol; 2018 Feb; 19(2):229-239. PubMed ID: 29361469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
    Perm J; 2020; 24():. PubMed ID: 32097116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma.
    Garnier M; Zaragoza J; Bénéton N; Bens G; Meurisse V; Samimi M; Maillard H; Machet L
    J Am Acad Dermatol; 2018 Jul; 79(1):165-167.e2. PubMed ID: 29544740
    [No Abstract]   [Full Text] [Related]  

  • 29. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with immunotherapy selection in patients with advanced melanoma.
    Joseph RW; Shillington AC; Macahilig C; Diede SJ; Dave V; Harshaw Q; Liu FX
    Immunotherapy; 2018 Nov; 10(16):1361-1369. PubMed ID: 30407098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
    Moser JC; Wei G; Colonna SV; Grossmann KF; Patel S; Hyngstrom JR
    Acta Oncol; 2020 Apr; 59(4):434-437. PubMed ID: 31920132
    [No Abstract]   [Full Text] [Related]  

  • 40. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
    J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.